{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T04:05:32Z","timestamp":1794110732917,"version":"4.8.0"},"reference-count":154,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA211861, R61AI133697"],"award-info":[{"award-number":["R01CA211861, R61AI133697"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Chimeric antigen receptor (CAR) T cell therapy represents a major breakthrough in cancer care since the approval of tisagenlecleucel by the Food and Drug Administration in 2017 for the treatment of pediatric and young adult patients with relapsed or refractory acute lymphocytic leukemia. As of April 2023, six CAR T cell therapies have been approved, demonstrating unprecedented efficacy in patients with B-cell malignancies and multiple myeloma. However, adverse events such as cytokine release syndrome and immune effector cell-associated neurotoxicity pose significant challenges to CAR T cell therapy. The severity of these adverse events correlates with the pretreatment tumor burden, where a higher tumor burden results in more severe consequences. This observation is supported by the application of CD19-targeted CAR T cell therapy in autoimmune diseases including systemic lupus erythematosus and antisynthetase syndrome. These results indicate that initiating CAR T cell therapy early at low tumor burden or using debulking strategy prior to CAR T cell infusion may reduce the severity of adverse events. In addition, CAR T cell therapy is expensive and has limited effectiveness against solid tumors. In this article, we review the critical steps that led to this groundbreaking therapy and explore ongoing efforts to overcome these challenges. With the promise of more effective and safer CAR T cell therapies in development, we are optimistic that a broader range of cancer patients will benefit from this revolutionary therapy in the foreseeable future.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1188049","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:41:37Z","timestamp":1684111297000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":487,"title":["From bench to bedside: the history and progress of CAR T cell therapy"],"prefix":"10.3389","volume":"14","author":[{"given":"Aroshi","family":"Mitra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita","family":"Barua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhartha","family":"Ganguly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02965","article-title":"The intriguing history of cancer immunotherapy","volume":"10","author":"Dobosz","year":"2019","journal-title":"Front Immunol"},{"key":"B2","article-title":"The toxins of William b. coley and the treatment of bone and soft-tissue sarcomas","volume":"26","author":"Mccarthy","year":"2006","journal-title":"Iowa Orthop J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-26-4143","article-title":"On the pathological relations between cancer and tuberculosis","volume":"26","author":"Pearl","year":"1928","journal-title":"Proc Soc Exp Biol Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary bacillus calmette-guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer\u2013a current perspective","volume":"11","author":"Redelman-Sidi","year":"2014","journal-title":"Nat Rev Urol"},{"key":"B6","article-title":"Antitumor effects of interferon preparations in mice","volume":"45","author":"Gresser","year":"1970","journal-title":"J Natl Cancer Inst"},{"key":"B7","doi-asserted-by":"publisher","first-page":"399","DOI":"10.7326\/0003-4819-93-3-399","article-title":"Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma","volume":"93","author":"Gutterman","year":"1980","journal-title":"Ann Intern Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198401053100104","article-title":"Alpha interferon for induction of remission in hairy-cell leukemia","volume":"310","author":"Quesada","year":"1984","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.6.900","article-title":"Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients","volume":"4","author":"Golomb","year":"1986","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2004.04.002","article-title":"The phenomenology and treatment of interferon-induced depression","volume":"82","author":"Loftis","year":"2004","journal-title":"J Affect Disord"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/302305a0","article-title":"Structure and expression of a cloned cDNA for human interleukin-2","volume":"302","author":"Taniguchi","year":"1983","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198704093161501","article-title":"A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone","volume":"316","author":"Rosenberg","year":"1987","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"13","author":"Fyfe","year":"1995","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz398","article-title":"Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis","volume":"30","author":"Dafni","year":"2019","journal-title":"Ann Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01445-z","article-title":"Tumor-infiltrating lymphocytes make inroads in non-small-cell lung cancer","volume":"27","author":"Veatch","year":"2021","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197905103001902","article-title":"Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts","volume":"300","author":"Weiden","year":"1979","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.11.3390","article-title":"Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects","volume":"97","author":"Mcsweeney","year":"2001","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma","volume":"210","author":"Simpson","year":"2013","journal-title":"J Exp Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0402","article-title":"Anti-CTLA-4 immunotherapy does not deplete FOXP3(+) regulatory T cells (Tregs) in human cancers-response","volume":"25","author":"Sharma","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/74704","article-title":"Inhibitory fc receptors modulate in vivo cytoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1126\/science.3489291","article-title":"A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes","volume":"233","author":"Rosenberg","year":"1986","journal-title":"Science"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. a preliminary report","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.7220","article-title":"Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma","volume":"34","author":"Goff","year":"2016","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.07.013","article-title":"Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors","volume":"38","author":"Leko","year":"2020","journal-title":"Cancer Cell"},{"key":"B28","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(87)90502-X","article-title":"Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived c regions","volume":"149","author":"Kuwana","year":"1987","journal-title":"Biochem Biophys Res Commun"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-t-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1126\/science.3140379","article-title":"Single-chain antigen-binding proteins","volume":"242","author":"Bird","year":"1988","journal-title":"Science"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.85.16.5879","article-title":"Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain fv analogue produced in escherichia coli","volume":"85","author":"Huston","year":"1988","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s002620050415","article-title":"Tumor-specific T-bodies: towards clinical application","volume":"45","author":"Eshhar","year":"1997","journal-title":"Cancer Immunol Immunother"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.10.4318","article-title":"Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells","volume":"91","author":"Moritz","year":"1994","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1084\/jem.178.1.361","article-title":"Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the fc receptor gamma chain","volume":"178","author":"Hwu","year":"1993","journal-title":"J Exp Med"},{"key":"B37","article-title":"In vivo antitumor activity of T cells redirected with chimeric antibody\/T-cell receptor genes","volume":"55","author":"Hwu","year":"1995","journal-title":"Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.157.2.836","article-title":"Single chain ig\/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity","volume":"157","author":"Weijtens","year":"1996","journal-title":"J Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.05.9964","article-title":"Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience","volume":"24","author":"Lamers","year":"2006","journal-title":"J Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-12-128843","article-title":"Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells","volume":"112","author":"Till","year":"2008","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mt.6300104","article-title":"Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma","volume":"15","author":"Park","year":"2007","journal-title":"Mol Ther"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1882","article-title":"Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma","volume":"14","author":"Pule","year":"2008","journal-title":"Nat Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.14.1.233","article-title":"CD28\/B7 system of T cell costimulation","volume":"14","author":"Lenschow","year":"1996","journal-title":"Annu Rev Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1084\/jem.188.4.619","article-title":"Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes","volume":"188","author":"Krause","year":"1998","journal-title":"J Exp Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta\/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat Biotechnol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients","volume":"121","author":"Savoldo","year":"2011","journal-title":"J Clin Invest"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.1.104","article-title":"Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain","volume":"172","author":"Finney","year":"2004","journal-title":"J Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol Ther"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of b-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory b-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T Cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Trans Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1126\/science.1076514","article-title":"Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes","volume":"298","author":"Dudley","year":"2002","journal-title":"Science"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.00.240","article-title":"Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma","volume":"23","author":"Dudley","year":"2005","journal-title":"J Clin Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with b-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large b-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large b-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"B62","doi-asserted-by":"crossref","DOI":"10.1201\/9781003124542-28","article-title":"Cellular-based therapies","volume-title":"Translational medicine","author":"Feigal","year":"2021"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-Cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-Year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02262","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with b-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in b-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-167789","article-title":"Long-term follow-up of CD19\/22 CAR therapy in children and young adults with b-ALL reveals efficacy, tolerability and high survival rates when coupled with hematopoietic stem cell transplantation","volume":"140","author":"Schultz","year":"2022","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009515","article-title":"Interventions and outcomes of adult patients with b-ALL progressing after CD19 chimeric antigen receptor T-cell therapy","volume":"138","author":"Wudhikarn","year":"2021","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-457531","article-title":"T Cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-629527","article-title":"A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies","volume":"126","author":"Mamonkin","year":"2015","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4444","article-title":"Targeting the T cell receptor beta-chain constant region for immunotherapy of T cell malignancies","volume":"23","author":"Maciocia","year":"2017","journal-title":"Nat Med"},{"key":"B73","doi-asserted-by":"publisher","first-page":"4334","DOI":"10.1038\/s41467-022-32092-8","article-title":"T Cell receptor beta-chain-targeting chimeric antigen receptor T cells against T cell malignancies","volume":"13","author":"Li","year":"2022","journal-title":"Nat Commun"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01467","article-title":"Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy","volume":"38","author":"Cappell","year":"2020","journal-title":"J Clin Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-023-00593-3","article-title":"Long-term response to autologous anti-CD19 chimeric antigen receptor T cells in relapsed or refractory b cell acute lymphoblastic leukemia: a systematic review and meta-analysis","author":"Elsallab","year":"2023","journal-title":"Cancer Gene Ther"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01969-y","article-title":"A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large b cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat Med"},{"key":"B78","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/diseases10030041","article-title":"Interleukin inhibitors in cytokine release syndrome and neurotoxicity secondary to CAR-T therapy","volume":"10","author":"Ferreros","year":"2022","journal-title":"Diseases"},{"key":"B79","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-6367(23)00234-8","article-title":"Interim analysis of investigator-initiated phase 2 trial of siltuximab in treatment of cytokine release syndrome and immune effector cell associated neurotoxicity related to CAR T-cell therapy","volume-title":"2023 tandem meetings| transplantation & cellular therapy meetings of ASTCT and CIBMTR","author":"Narkhede","year":"2023"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"B82","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.cell.2020.08.022","article-title":"Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies","volume":"183","author":"Parker","year":"2020","journal-title":"Cell"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"B84","doi-asserted-by":"publisher","first-page":"177ra138","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med"},{"key":"B85","doi-asserted-by":"publisher","first-page":"224ra225","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in b cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"B86","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41598-021-04296-3","article-title":"The differential effects of tumor burdens on predicting the net benefits of ssCART-19 cell treatment on r\/r b-ALL patients","volume":"12","author":"Li","year":"2022","journal-title":"Sci Rep"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"Lancet (London, England)"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25595","article-title":"Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment","volume":"94","author":"Hallek","year":"2019","journal-title":"Am J Hematol"},{"key":"B91","article-title":"Acute lymphocytic leukemia","volume-title":"StatPearls","author":"Puckett","year":"2022"},{"key":"B92","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/art.1780210302","article-title":"Lymphopenia in systemic lupus erythematosus. clinical, diagnostic, and prognostic significance","volume":"21","author":"Rivero","year":"1978","journal-title":"Arthritis Rheum"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.4.2361","article-title":"Increased frequency of pre-germinal center b cells and plasma cell precursors in the blood of children with systemic lupus erythematosus","volume":"167","author":"Arce","year":"2001","journal-title":"J Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2019.04.014","article-title":"Mass cytometry reveals an impairment of b cell homeostasis in anti-synthetase syndrome","volume":"332","author":"Dzangue-Tchoupou","year":"2019","journal-title":"J Neuroimmunol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2668","article-title":"Current understanding of tumor lysis syndrome","volume":"37","author":"Rahmani","year":"2019","journal-title":"Hematol Oncol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0977","article-title":"Total costs of chimeric antigen receptor T-cell immunotherapy","volume":"4","author":"Hernandez","year":"2018","journal-title":"JAMA Oncol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0508","article-title":"Genetic ablation of HLA class I, class II, and the T-cell receptor enables allogeneic T cells to be used for adoptive T-cell therapy","volume":"8","author":"Kagoya","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02306-7","article-title":"Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results","volume":"29","author":"Mailankody","year":"2023","journal-title":"Nat Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/344742a0","article-title":"Beta 2-microglobulin deficient mice lack CD4-8+ cytolytic T cells","volume":"344","author":"Zijlstra","year":"1990","journal-title":"Nature"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-169114","article-title":"Tvt CAR7: phase 1 clinical trial of base-edited universal\u201d CAR7 T cells for paediatric Relapsed\/Refractory T-ALL","volume":"140","author":"Chiesa","year":"2022","journal-title":"Blood"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015825","article-title":"Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL","volume":"140","author":"Diorio","year":"2022","journal-title":"Blood"},{"key":"B103","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1038\/s41467-022-30896-2","article-title":"Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing","volume":"13","author":"Jo","year":"2022","journal-title":"Nat Commun"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"B105","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.omtm.2022.05.006","article-title":"Selective b cell depletion upon intravenous infusion of replication-incompetent anti-CD19 CAR lentivirus","volume":"26","author":"Rive","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162393","article-title":"Interleukin-18 secreting autologous anti-CD19 CAR T-cells (huCART19-IL18) in patients with non-Hodgkin lymphomas relapsed or refractory to prior CAR T-cell therapy","volume":"140","author":"Svoboda","year":"2022","journal-title":"Blood"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-021-00842-6","article-title":"Rapid manufacturing of non-activated potent CAR T cells","volume":"6","author":"Ghassemi","year":"2022","journal-title":"Nat BioMed Eng"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2015.4","article-title":"Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression","volume":"23","author":"Curran","year":"2015","journal-title":"Mol Ther"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-negative TGF-beta receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol Ther"},{"key":"B110","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2019.02.006","article-title":"CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response","volume":"35","author":"Kuhn","year":"2019","journal-title":"Cancer Cell"},{"key":"B111","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.cmet.2022.02.009","article-title":"A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy","volume":"34","author":"Ye","year":"2022","journal-title":"Cell Metab"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba1624","article-title":"Synthetic cytokine circuits that drive T cells into immune-excluded tumors","volume":"378","author":"Allen","year":"2022","journal-title":"Science"},{"key":"B114","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells","volume":"7","author":"Rupp","year":"2017","journal-title":"Sci Rep"},{"key":"B115","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s40425-019-0806-7","article-title":"CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma","volume":"7","author":"Choi","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05692-z","article-title":"TET2 guards against unchecked BATF3-induced CAR T cell expansion","volume":"615","author":"Jain","year":"2023","journal-title":"Nature"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-0985-x","article-title":"NR4A transcription factors limit CAR T cell function in solid tumours","volume":"567","author":"Chen","year":"2019","journal-title":"Nature"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1821-z","article-title":"Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy","volume":"576","author":"Wei","year":"2019","journal-title":"Nature"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009309","article-title":"Regnase-1 suppresses TCF-1+ precursor exhausted T-cell formation to limit CAR-t-cell responses against ALL","volume":"138","author":"Zheng","year":"2021","journal-title":"Blood"},{"key":"B120","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/jha2.356","article-title":"CAR T cell therapy in solid tumors: a review of current clinical trials","volume":"3","author":"Patel","year":"2022","journal-title":"EJHaem"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26914","article-title":"Hypogammaglobulinemia due to CAR T-cell therapy","volume":"65","author":"Pulsipher","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"B122","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2217\/imt.10.81","article-title":"Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer","volume":"3","author":"Duong","year":"2011","journal-title":"Immunotherapy"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2459","article-title":"Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells","volume":"31","author":"Kloss","year":"2013","journal-title":"Nat Biotechnol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01 for relapsed or refractory high-risk neuroblastoma","volume":"388","author":"Del Bufalo","year":"2023","journal-title":"N Engl J Med"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.4161\/onci.19864","article-title":"Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo","volume":"1","author":"Cheung","year":"2012","journal-title":"Oncoimmunology"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.06.008","article-title":"Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase","volume":"25","author":"Walker","year":"2017","journal-title":"Mol Ther"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021010813","article-title":"Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells","volume":"138","author":"Bishop","year":"2021","journal-title":"Blood"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021010858","article-title":"Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells","volume":"138","author":"Micklethwaite","year":"2021","journal-title":"Blood"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4564","article-title":"An inducible caspase 9 safety switch for T-cell therapy","volume":"105","author":"Straathof","year":"2005","journal-title":"Blood"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1177\/00912700122010771","article-title":"Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers","volume":"41","author":"Iuliucci","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021010784","article-title":"Utility of a safety switch to abrogate CD19.CAR T-cell-associated neurotoxicity","volume":"137","author":"Foster","year":"2021","journal-title":"Blood"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.03.001","article-title":"A rapamycin-activated caspase 9-based suicide gene","volume":"26","author":"Stavrou","year":"2018","journal-title":"Mol Ther"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2008.001677","article-title":"Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy","volume":"94","author":"Griffioen","year":"2009","journal-title":"Haematologica"},{"key":"B135","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1182\/blood.V126.23.565.565","article-title":"Efficient termination of CD123-redirected chimeric antigen receptor T cells for acute myeloid leukemia to mitigate toxicity","volume":"126","author":"Tasian","year":"2015","journal-title":"Blood"},{"key":"B136","doi-asserted-by":"publisher","first-page":"8972","DOI":"10.1038\/s41598-018-27264-w","article-title":"A versatile safeguard for chimeric antigen receptor T-cell immunotherapies","volume":"8","author":"Valton","year":"2018","journal-title":"Sci Rep"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.04.001","article-title":"Preclinical evaluation of allogeneic CAR T cells targeting BCMA for the treatment of multiple myeloma","volume":"27","author":"Sommer","year":"2019","journal-title":"Mol Ther"},{"key":"B138","doi-asserted-by":"publisher","first-page":"aab4077","DOI":"10.1126\/science.aab4077","article-title":"Remote control of therapeutic T cells through a small molecule-gated chimeric receptor","volume":"350","author":"Wu","year":"2015","journal-title":"Science"},{"key":"B139","doi-asserted-by":"publisher","first-page":"4551","DOI":"10.1182\/blood.V128.22.4551.4551","article-title":"Inducible MyD88\/CD40 (iMC) costimulation provides ligand-dependent tumor eradication by CD123-specific chimeric antigen receptor T cells","volume":"128","author":"Foster","year":"2016","journal-title":"Blood"},{"key":"B140","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/j.cell.2022.03.041","article-title":"Enhanced safety and efficacy of protease-regulated CAR-T cell receptors","volume":"185","author":"Labanieh","year":"2022","journal-title":". Cell"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1126\/science.ade0156","article-title":"Multidimensional control of therapeutic human cell function with synthetic gene circuits","volume":"378","author":"Li","year":"2022","journal-title":"Science"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci Transl Med"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018028720","article-title":"Pharmacologic control of CAR-T cell function using dasatinib","volume":"3","author":"Weber","year":"2019","journal-title":"Blood Adv"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.3.785.015k10_785_793","article-title":"Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects","volume":"96","author":"Mitsuyasu","year":"2000","journal-title":"Blood"},{"key":"B145","doi-asserted-by":"publisher","first-page":"132ra153","DOI":"10.1126\/scitranslmed.3003761","article-title":"Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells","volume":"4","author":"Scholler","year":"2012","journal-title":"Sci Transl Med"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1546-z","article-title":"Targeting cardiac fibrosis with engineered T cells","volume":"573","author":"Aghajanian","year":"2019","journal-title":"Nature"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2403-9","article-title":"Senolytic CAR T cells reverse senescence-associated pathologies","volume":"583","author":"Amor","year":"2020","journal-title":"Nature"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02711","article-title":"CAR T cells beyond cancer: hope for immunomodulatory therapy of infectious diseases","volume":"10","author":"Seif","year":"2019","journal-title":"Front Immunol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1074-2","article-title":"Anti-GD2 CAR-NKT cellsin patients with relapsed or refractory neuroblastoma: an interim analysis","volume":"26","author":"Heczey","year":"2020","journal-title":"Nat Med"},{"key":"B150","doi-asserted-by":"publisher","first-page":"103873","DOI":"10.1016\/j.ebiom.2022.103873","article-title":"CAR-macrophage: an extensive immune enhancer to fight cancer","volume":"76","author":"Wang","year":"2022","journal-title":"EBioMedicine"},{"key":"B151","doi-asserted-by":"publisher","first-page":"111128","DOI":"10.1016\/j.celrep.2022.111128","article-title":"Engineering chimeric antigen receptor neutrophils from human pluripotent stem cells for targeted cancer immunotherapy","volume":"40","author":"Chang","year":"2022","journal-title":"Cell Rep"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"B153","doi-asserted-by":"publisher","first-page":"eadf3700","DOI":"10.1126\/sciadv.adf3700","article-title":"TCR-engineered T cell therapy in solid tumors: state of the art and perspectives","volume":"9","author":"Baulu","year":"2023","journal-title":"Sci Adv"},{"key":"B154","doi-asserted-by":"publisher","first-page":"5271","DOI":"10.1038\/s41467-021-25605-4","article-title":"Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens","volume":"12","author":"Hwang","year":"2021","journal-title":"Nat Commun"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1188049\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:41:46Z","timestamp":1684111306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1188049\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,15]]},"references-count":154,"alternative-id":["10.3389\/fimmu.2023.1188049"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1188049","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,15]]},"article-number":"1188049"}}